Renaissance Technologies (RenTech)'s CYTK Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 172,067 shares of Cytokinetics, Incorporated (CYTK) worth $10.93 M, representing 0.02% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CYTK, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 330,000 shares. Largest reduction occurred in Q4 2014, reducing 498,161 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Cytokinetics Incorporated (CYTK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytokinetics Incorporated (CYTK) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -117,900 | Reduce 40.66% | 172,067 | $63.54 |
| Q3 2025 | +279,800 | Add 2752.04% | 289,967 | $54.96 |
| Q2 2025 | -110,500 | Reduce 91.57% | 10,167 | $33.04 |
| Q1 2025 | -71,500 | Reduce 37.21% | 120,667 | $40.19 |
| Q4 2024 | -52,200 | Reduce 21.36% | 192,167 | $47.04 |
| Q3 2024 | -226,600 | Reduce 48.11% | 244,367 | $52.80 |
| Q2 2024 | +105,000 | Add 28.69% | 470,967 | $54.18 |
| Q1 2024 | +330,000 | Add 917.51% | 365,967 | $70.11 |
| Q4 2023 | +35,967 | New Buy | 35,967 | $83.49 |
| Q1 2023 | -73,667 | Sold Out | 0 | $0.00 |
| Q4 2022 | +73,667 | New Buy | 73,667 | $0.05 |
| Q4 2021 | -338,367 | Sold Out | 0 | $0.00 |
| Q3 2021 | +267,600 | Add 378.14% | 338,367 | $35.74 |
| Q2 2021 | +70,767 | New Buy | 70,767 | $19.78 |
| Q3 2020 | -71,067 | Sold Out | 0 | $0.00 |
| Q2 2020 | +71,067 | New Buy | 71,067 | $23.57 |
| Q1 2020 | -153,767 | Sold Out | 0 | $0.00 |
| Q4 2019 | +83,467 | Add 118.73% | 153,767 | $10.61 |
| Q3 2019 | -298,000 | Reduce 80.91% | 70,300 | $11.38 |
| Q2 2019 | +93,000 | Add 33.78% | 368,300 | $11.25 |
| Q1 2019 | +256,100 | Add 1333.85% | 275,300 | $8.09 |
| Q4 2018 | +19,200 | New Buy | 19,200 | $6.30 |
| Q2 2016 | -184,479 | Sold Out | 0 | $0.00 |
| Q1 2016 | -334,799 | Reduce 64.47% | 184,479 | $7.05 |
| Q4 2015 | +299,578 | Add 136.36% | 519,278 | $10.46 |
| Q3 2015 | +147,300 | Add 203.45% | 219,700 | $6.69 |
| Q2 2015 | +2,933 | Add 4.22% | 72,400 | $6.73 |
| Q1 2015 | +69,467 | New Buy | 69,467 | $6.78 |
| Q4 2014 | -498,161 | Sold Out | 0 | $0.00 |
| Q3 2014 | +240,624 | Add 93.43% | 498,161 | $3.52 |
| Q2 2014 | +69,470 | Add 36.94% | 257,537 | $4.78 |
| Q1 2014 | -147,200 | Reduce 43.91% | 188,067 | $9.50 |
| Q4 2013 | +335,267 | New Buy | 335,267 | $6.50 |
Renaissance Technologies (RenTech)'s Cytokinetics Incorporated Investment FAQs
Renaissance Technologies (RenTech) first purchased Cytokinetics, Incorporated (CYTK) in Q4 2013, acquiring 335,267 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Cytokinetics, Incorporated (CYTK) for 33 quarters since Q4 2013.
Renaissance Technologies (RenTech)'s largest addition to Cytokinetics, Incorporated (CYTK) was in Q4 2013, adding 335,267 shares worth $2.18 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 172,067 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $10.93 M.
As of the Q4 2025 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Cytokinetics, Incorporated (CYTK) was 519,278 shares, as reported at the end of Q4 2015.